Skip to main content
AAN.com

Abstract

Objective

To determine if survival and cognitive profile is affected by initial presentation in amyotrophic lateral sclerosis–frontotemporal dementia (ALS-FTD) (motor vs cognitive), we compared survival patterns in ALS-FTD based on initial phenotypic presentation and their cognitive profile compared to behavioral variant FTD (bvFTD).

Methods

Cognitive/behavioral profiles were examined in 98 patients (59 ALS-FTD and 39 bvFTD). The initial presentation of ALS-FTD was categorized into either motor or cognitive. Survival was calculated from initial symptom onset. MRI brain atrophy patterns were examined using a validated visual rating scale.

Results

In the ALS-FTD group, 41 (69%) patients were categorized as having an initial cognitive presentation and 18 (31%) a motor presentation. Patients with motor presentation experienced a significantly shorter median survival of 2.7 years compared to 4.4 years (p < 0.001) in those with a cognitive presentation. No differences between motor vs cognitive onset ALS-FTD were found on cognitive testing. When compared to bvFTD, ALS-FTD–cognitive presentation was characterized by reduced language function (p < 0.001), verbal fluency (p = 0.001), and naming (p = 0.007). Both motor and cognitive onset ALS-FTD showed reduced emotion processing (p = 0.01) and exhibited greater motor cortex and dorsal lateral prefrontal cortex atrophy than bvFTD. Increased motor cortex atrophy was associated with 1.5-fold reduction in survival.

Conclusions

Initial motor presentation in ALS-FTD leads to faster progression than in those with a cognitive presentation, despite similar overall cognitive deficits. These findings suggest that disease progression in ALS-FTD may be critically linked to physiologic and motor changes.

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
Lomen-Hoerth C, Anderson T, Miller B. The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology 2002;59:1077–1079.
2.
Clark CM, Forman MS. Frontotemporal lobar degeneration with motor neuron disease: a clinical and pathological spectrum. Arch Neurol 2006;63:489–490.
3.
Hodges J. Familial frontotemporal dementia and amyotrophic lateral sclerosis associated with the C9ORF72 hexanucleotide repeat. Brain 2012;135:652–655.
4.
Mitsuyama Y, Inoue T. Clinical entity of frontotemporal dementia with motor neuron disease. Neuropathology 2009;29:649–654.
5.
Turner MR, Hardiman O, Benatar M, et al. Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol 2013;12:310–322.
6.
Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis. Lancet 2011;377:942–955.
7.
Vucic S, Rothstein JD, Kiernan MC. Advances in treating amyotrophic lateral sclerosis: insights from pathophysiological studies. Trends Neurosci 2014;37:433–442.
8.
Strong MJ. The syndromes of frontotemporal dysfunction in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2008;9:323–338.
9.
Montuschi A, Iazzolino B, Calvo A, et al. Cognitive correlates in amyotrophic lateral sclerosis: a population-based study in Italy. J Neurol Neurosurg Psychiatry 2015;86:168–173.
10.
Ringholz GM, Appel SH, Bradshaw M, Cooke NA, Mosnik DM, Schulz PE. Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology 2005;65:586–590.
11.
Burrell JR, Kiernan MC, Vucic S, Hodges JR. Motor neuron dysfunction in frontotemporal dementia. Brain 2011;134:2582–2594.
12.
Ludolph AC, Brettschneider J. TDP-43 in amyotrophic lateral sclerosis: is it a prion disease? Eur J Neurol 2015;22:753–761.
13.
Braak H, Brettschneider J, Ludolph AC, Lee VM, Trojanowski JQ, Del Tredici K. Amyotrophic lateral sclerosis: a model of corticofugal axonal spread. Nat Rev Neurol 2013;9:708–714.
14.
Tan RH, Kril JJ, Fatima M, et al. TDP-43 proteinopathies: pathological identification of brain regions differentiating clinical phenotypes. Brain 2015;138:3110–3122.
15.
Brettschneider J, Del Tredici K, Toledo JB, et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol 2013;74:20–38.
16.
Lule DE, Aho-Ozhan HEA, Vazquez C, et al. Story of the ALS-FTD continuum retold: rather two distinct entities. J Neurol Neurosurg Psychiatry 2019;90:586–589.
17.
Saxon JA, Thompson JC, Jones M, et al. Examining the language and behavioural profile in FTD and ALS-FTD. J Neurol Neurosurg Psychiatry 2017;88:675–680.
18.
Hodges JR, Davies R, Xuereb J, Kril J, Halliday G. Survival in frontotemporal dementia. Neurology 2003;61:349–354.
19.
Hu WT, Seelaar H, Josephs KA, et al. Survival profiles of patients with frontotemporal dementia and motor neuron disease. Arch Neurol 2009;66:1359–1364.
20.
Strong MJ, Abrahams S, Goldstein LH, et al. Amyotrophic lateral sclerosis–frontotemporal spectrum disorder (ALS-FTSD): revised diagnostic criteria. Amyotroph Lateral Scler Frontotemporal Degener 2017;18:153–174.
21.
Abrahams S, Leigh PN, Harvey A, Vythelingum GN, Grise D, Goldstein LH. Verbal fluency and executive dysfunction in amyotrophic lateral sclerosis (ALS). Neuropsychologia 2000;38:734–747.
22.
Mioshi E, Dawson K, Mitchell J, Arnold R, Hodges JR. The Addenbrooke's Cognitive Examination Revised (ACE-R): a brief cognitive test battery for dementia screening. Int J Geriatr Psychiatry 2006;21:1078–1085.
23.
Rey A. l’Examen psychologique dans les cas d'encéphalopathie traumatique. Arch Psychol 1941;28:215–285.
24.
Savage SA, Hsieh S, Leslie F, Foxe D, Piguet O, Hodges JR. Distinguishing subtypes in primary progressive aphasia: application of the Sydney language battery. Demen Geriatr Cogn Disord 2013;35:208–218.
25.
Schmidt M. Rey Auditory Verbal Learning Test: A Handbook. Los Angeles: Western Psychological Services; 1996.
26.
Burgess P, Shallice T, ed. The Hayling and Brixton Tests. Thurston Suffolk: Thames Valley Test Company; 1997.
27.
Strauss E, Sherman EMS, Spreen O. A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary. Oxford: Oxford University Press; 2006.
28.
Miller LA, Hsieh S, Lah S, Savage S, Hodges JR, Piguet O. One size does not fit all: face emotion processing impairments in semantic dementia, behavioural-variant frontotemporal dementia and Alzheimer's disease are mediated by distinct cognitive deficits. Behav Neurol 2012;25:53–60.
29.
Wedderburn C, Wear H, Brown J, et al. The utility of the Cambridge Behavioural Inventory in neurodegenerative disease. J Neurol Neurosurg Psychiatry 2008;79:500–503.
30.
Ambikairajah A, Devenney E, Flanagan E, et al. A visual MRI atrophy rating scale for the amyotrophic lateral sclerosis–frontotemporal dementia continuum. Amyotroph Lateral Scler Frontotemporal Degener 2014;15:226–234.
31.
Lillo P, Mioshi E, Burrell JR, Kiernan MC, Hodges JR, Hornberger M. Grey and white matter changes across the amyotrophic lateral sclerosis–frontotemporal dementia continuum. PLoS One 2012;7:e43993.
32.
Chen Z, Ma L. Grey matter volume changes over the whole brain in amyotrophic lateral sclerosis: a voxel-wise meta-analysis of voxel based morphometry studies. Amyotroph Lateral Scler 2010;11:549–554.
33.
Mezzapesa DM, Ceccarelli A, Dicuonzo F, et al. Whole-brain and regional brain atrophy in amyotrophic lateral sclerosis. AJNR Am J Neuroradiol 2007;28:255–259.
34.
Ahmed RM, Devenney EM, Irish M, et al. Neuronal network disintegration: common pathways linking neurodegenerative diseases. J Neurol Neurosurg Psychiatry 2016;87:1234–1241.
35.
Ahmed RM, Ke YD, Vucic S, et al. Physiological changes in neurodegeneration: mechanistic insights and clinical utility. Nat Rev Neurol 2018;14:259–271.
36.
Verstraete E, Veldink JH, Mandl RC, van den Berg LH, van den Heuvel MP. Impaired structural motor connectome in amyotrophic lateral sclerosis. PLoS One 2011;6:e24239.
37.
Ahmed RM, Irish M, Piguet O, et al. Amyotrophic lateral sclerosis and frontotemporal dementia: distinct and overlapping changes in eating behaviour and metabolism. Lancet Neurol 2016;15:332–342.
38.
Henderson RD, Garton FC, Kiernan MC, Turner MR, Eisen A. Human cerebral evolution and the clinical syndrome of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2019;90:570–575.
39.
Irwin DJ, McMillan CT, Brettschneider J, et al. Cognitive decline and reduced survival in C9orf72 expansion frontotemporal degeneration and amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2013;84:163–169.
40.
Lillo P, Garcin B, Hornberger M, Bak TH, Hodges JR. Neurobehavioral features in frontotemporal dementia with amyotrophic lateral sclerosis. Arch Neurol 2010;67:826–830.
41.
Lomen-Hoerth C, Murphy J, Langmore S, Kramer JH, Olney RK, Miller B. Are amyotrophic lateral sclerosis patients cognitively normal? Neurology 2003;60:1094–1097.
42.
Rippon GA, Scarmeas N, Gordon PH, et al. An observational study of cognitive impairment in amyotrophic lateral sclerosis. Arch Neurol 2006;63:345–352.
43.
Long Z, Irish M, Piguet O, Kiernan MC, Hodges JR, Burrell JR. Clinical and neuroimaging investigations of language disturbance in frontotemporal dementia–motor neuron disease patients. J Neurol 2019;266:921–933.
44.
Vinceti G, Olney N, Mandelli ML, et al. Primary progressive aphasia and the FTD-MND spectrum disorders: clinical, pathological, and neuroimaging correlates. Amyotroph Lateral Scler Frontotemporal Degener 2019;20:146–158.
45.
Miller EK, Cohen JD. An integrative theory of prefrontal cortex function. Annu Rev Neurosci 2001;24:167–202.
46.
Wood JN, Grafman J. Human prefrontal cortex: processing and representational perspectives. Nat Rev Neurosci 2003;4:139–147.
47.
Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011;134:2456–2477.
48.
Savage SA, Lillo P, Kumfor F, Kiernan MC, Piguet O, Hodges JR. Emotion processing deficits distinguish pure amyotrophic lateral sclerosis from frontotemporal dementia. Amyotroph Lateral Scler Frontotemporal Degener 2014;15:39–46.
Letters to the Editor
20 April 2020
Author response: Phenotypic variability in ALS-FTD and effect on survival
Rebekah M. Ahmed, Neurologist| University of Sydney
Matthew C. Kiernan, Neurologist| University of Sydney

We thank Dr. Abe for his interest in our study1 that investigated survival in amyotrophic lateral sclerosis-frontotemporal dementia (ALS- FTD) patients. Specific comparison of motor and cognitive presentations in ALS-FTD established that patients with a motor-onset of their disease had reduced survival—which was associated with increased motor cortex atrophy—suggesting that survival may be mediated by motor function and other critical physiological aspects.

We agree that ALS-FTD can present with behavioral and cognitive changes, as has been documented in well-characterized case series.2–4

A key aim of the present study was to understand how this cognitive, behavioral profile differs from behavioral variant frontotemporal dementia (bvFTD). We found that those with ALS-FTD with an initial cognitive presentation have more prominent language changes and both ALS-FTD motor and cognitive presentation have greater deficits in emotion processing than bvFTD—which is a new finding and requires further investigation—as traditionally bvFTD has been regarded as having the greatest emotion processing deficits.5

Further studies are currently underway to better dissect the presentations and phenotypes across the ALS-FTD spectrum. Such studies should include both clinical, structural, functional, and pathological evaluation to better characterize the commonalities and differences across the ALS-FTD spectrum.

Disclosure

The authors report no relevant disclosures. Contact [email protected] for full disclosures.

References

  1. Ahmed RM, Devenney EM, Strikwerda-Brown C, Hodges JR, Piguet O, Kiernan MC. Phenotypic variability in ALS-FTD and effect on survival. Neurology 2020 Epub Apr 10.
  2. Burrell JR, Halliday GM, Kril JJ, et al. The frontotemporal dementia-motor neuron disease continuum. Lancet 2016;388:919–931.
  3. Lillo P, Mioshi E, Zoing MC, Kiernan MC, Hodges JR. How common are behavioural changes in amyotrophic lateral sclerosis? Amyotroph Lateral Scler 2011;12:45–51.
  4. Saxon JA, Thompson JC, Jones M, et al. Examining the language and behavioural profile in FTD and ALS-FTD. J Neurol Neurosurg Psychiatry 2017;88:675–80.
  5. Kumfor F, Piguet O. Disturbance of emotion processing in frontotemporal dementia: a synthesis of cognitive and neuroimaging findings. Neuropsychol Rev 2012;22:280–97.
13 April 2020
Reader response: Phenotypic variability in ALS-FTD and effect on survival
Kazuo Abe, Neurologist| Kyowakai

I read the article by Ahmed et al.1 and generally agree with their comments. However, I offer some insights.

First, Yuasa2 reported a case of amyotrophic lateral sclerosis (ALS) with dementia who presented impairment of personality, forgetfulness, and forced grasp before presenting muscle weakness. The patient showed brain atrophy in the frontal lobe. Following reports—including autopsies and neuroimages that supported ALS with dementia or motor neuron disease (MND) with dementia—showed atrophy, reduced blood flow, or hypometabolism characterized demonstrated in the central region and in the frontal lobe. The authors suggested that emotion processing and behavior disturbance had been considered core deficits in behavioral variant frontotemporal dementia (bvFTD) and thought to be less prominent in ALS-FTD. However, other studies including Yuasa’s suggested behavioral changes in ALS-FTD patients in their early stages. To elucidate these differences, morphological study does not have enough power, but functional imaging studies may hold advantages.3 We studied ALS patients with dementia by using SPECT and concluded ALS and ALS with dementia made a wide spectrum of a disease.4 The authors’ indication of atrophy in the dorsolateral prefrontal cortex (DLPFC) might be a key for differential diagnoses of variant types of ALS-FTD. I recently experienced an ALS-FTD patient who showed dominant bulbar palsy with forgetfulness but preserved personality. His SPECT showed reduced uptake in the central and prefrontal cortex not in the DLPFC.

I agree that further studies of ALS, ALS-FTD, and bvFTD are needed, but I suggest that function studies should be included in future projects.

Disclosure

The author reports no relevant disclosures. Contact [email protected] for full disclosures.

References

  1. Ahmed RM, Devenney EM, Strikwerda-Brown C, Hodges JR, Piguet O, Kiernan MC. Phenotypic variability in ALS-FTD and effect on survival. Neurology 2020 Epub Apr 10.
  2. Yuasa R. Amyotrophic lateral sclerosis with organic dementia: report of a case. Clin Neurol (Tokyo) 1964;4:529–534.
  3. Saxon JA, Thompson JC, Jones M, et al. Examining the language and behavioural profile in FTD and ALS-FTD. J Neurol Neurosurg Psychiatry 2017;88:675–680.
  4. Abe K, Fujimura H, Toyooka K, T Hazama, Hirono N, Yorifuji S, Yanagihara T. Single-photon emission computed tomographic investigation of patients with motor neuron disease. Neurology 1993;43:1569–1573.

Information & Authors

Information

Published In

Neurology®
Volume 94Number 19May 12, 2020
Pages: e2005-e2013
PubMed: 32277059

Publication History

Received: July 30, 2019
Accepted: November 16, 2019
Published online: April 10, 2020
Published in print: May 12, 2020

Permissions

Request permissions for this article.

Disclosure

The authors declare no relevant disclosures. Go to Neurology.org/N for full disclosures.

Study Funding

This work was supported in part by funding to Forefront, a collaborative research group dedicated to the study of frontotemporal dementia and motor neuron disease, from the National Health and Medical Research Council of Australia (NHMRC) program grant (1037746 to O.P., M.C.K., and J.R.H.) and the Australian Research Council Centre of Excellence in Cognition and its Disorders Memory Program (CE110001021 to O.P. and J.R.H.) and other grants/sources (NHMRC project grant 1003139 to O.P.) and Royal Australasian College of Physicians, MND Research Institute of Australia. R.M.A. is an NHMRC Early Career Fellow (1120770). O.P. is an NHMRC Senior Research Fellow (1103258). M.C.K. was supported by an NHMRC Practitioner Fellowship (1156093).

Authors

Affiliations & Disclosures

Rebekah M. Ahmed, PhD
From the Memory and Cognition Clinic, Department of Clinical Neurosciences (R.M.A., M.C.K.), Royal Prince Alfred Hospital; Central Sydney Medical School and Brain & Mind Centre (R.M.A., E.M.D., J.R.H., M.C.K.) and School of Psychology and Brain & Mind Centre (C.S.-B., O.P.), The University of Sydney; and ARC Centre of Excellence of Cognition and its Disorders (C.S.-B., O.P.), Sydney, Australia.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NHMRC Early career Fellowship
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Emma M. Devenney, PhD
From the Memory and Cognition Clinic, Department of Clinical Neurosciences (R.M.A., M.C.K.), Royal Prince Alfred Hospital; Central Sydney Medical School and Brain & Mind Centre (R.M.A., E.M.D., J.R.H., M.C.K.) and School of Psychology and Brain & Mind Centre (C.S.-B., O.P.), The University of Sydney; and ARC Centre of Excellence of Cognition and its Disorders (C.S.-B., O.P.), Sydney, Australia.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Dr E M Devenney is supported by a MNDRIA post-doctoral fellowship (PDF1073)
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Cherie Strikwerda-Brown, MPsych
From the Memory and Cognition Clinic, Department of Clinical Neurosciences (R.M.A., M.C.K.), Royal Prince Alfred Hospital; Central Sydney Medical School and Brain & Mind Centre (R.M.A., E.M.D., J.R.H., M.C.K.) and School of Psychology and Brain & Mind Centre (C.S.-B., O.P.), The University of Sydney; and ARC Centre of Excellence of Cognition and its Disorders (C.S.-B., O.P.), Sydney, Australia.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
John R. Hodges, MD
From the Memory and Cognition Clinic, Department of Clinical Neurosciences (R.M.A., M.C.K.), Royal Prince Alfred Hospital; Central Sydney Medical School and Brain & Mind Centre (R.M.A., E.M.D., J.R.H., M.C.K.) and School of Psychology and Brain & Mind Centre (C.S.-B., O.P.), The University of Sydney; and ARC Centre of Excellence of Cognition and its Disorders (C.S.-B., O.P.), Sydney, Australia.
Disclosure
Scientific Advisory Boards:
1.
Member Advisory Board – Nature Reviews, Neurology - non-profit entity
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Aphasiology (2000 - ) Cognitive Neuropsychology (2002- ) Nature Reviews (2005 - ) Journal of Alzheimer’s Disease, Associate Editor (2010 - ) Acta Neuropsychologica (2011 - ) ALS Journal (2011- ) Neurology and Clinical Neuroscience (NCN) (2013)
Patents:
1.
NONE
Publishing Royalties:
1.
OUP, Cognitive Assessment for Clinicians, 2007 CUP, Frontotemporal dementia Syndromes, 2007
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
Australian Research Council Federation fellowship, 2007 to 2012 National Health and Medical Research Council of Australia 2007 to 2015
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
From the Memory and Cognition Clinic, Department of Clinical Neurosciences (R.M.A., M.C.K.), Royal Prince Alfred Hospital; Central Sydney Medical School and Brain & Mind Centre (R.M.A., E.M.D., J.R.H., M.C.K.) and School of Psychology and Brain & Mind Centre (C.S.-B., O.P.), The University of Sydney; and ARC Centre of Excellence of Cognition and its Disorders (C.S.-B., O.P.), Sydney, Australia.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Frontiers in Dementia Research, Editorial Board, since 2011 Frontiers in Emotion Science, Editorial Board, since 2011 Behavioural Neurology, Editorial Board, since 2013 Brain Impairment, Editorial Board, since 2017 Neurodegenerative Disease Management, Editorial Board, since 2018
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
1) Australian Research Council, CE110001021, Centre of Excellence in Cognition and its Disorders, 2011-2018 2) National Health and Medical Research Council of Australia, APP1103258, Senior Research Fellowship 2016-2020
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
1) Velux Stiftung, Switzerland
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Matthew C. Kiernan, DSc
From the Memory and Cognition Clinic, Department of Clinical Neurosciences (R.M.A., M.C.K.), Royal Prince Alfred Hospital; Central Sydney Medical School and Brain & Mind Centre (R.M.A., E.M.D., J.R.H., M.C.K.) and School of Psychology and Brain & Mind Centre (C.S.-B., O.P.), The University of Sydney; and ARC Centre of Excellence of Cognition and its Disorders (C.S.-B., O.P.), Sydney, Australia.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Editor-in-Chief Journal of Neurology, Neurosurgery & Psychiatry (BMJ Publishing Group, UK); 2010 – present EDITORIAL ADVISORY BOARD: Journal of Clinical Neuroscience (Elsevier, UK): • Member Editorial Board 2004 – present • Associate Editor 2007 – 2013 Clinical Neurophysiology (Elsevier, UK): • Member Editorial Board 2007 – 2010 • Associate Editor 2008 – 2010 Amyotrophic Lateral Sclerosis (Taylor & Francis, UK): • Member Editorial Board 2008 – present Current Medicinal Chemistry (Bentham Press): • Member Editorial Board 2008 – present British Medical Journal (Case Reports): • Member Editorial Board 2008 – present British Medical Journal: • Member Editorial Board 2010 – 2014 British Medical Journal Open: • Member Editorial Advisory Board 2010 – present Practical Neurology: • Member Editorial Board 2010 – present
Patents:
1.
NONE
Publishing Royalties:
1.
Kiernan MC (Editor), “The Motor Neurone Disease Handbook”, MJA Books, Australasian Medical Publishing Company, Sydney, 2007, 225p
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
National Health & Medical Research Council (NH&MRC) of Australia: “Frontotemporal dementia and motor neurodegenerative syndromes”; Program Grant # 1037746; $11,362,045.48; Chief Investigator ; 2013-2018
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE

Notes

Correspondence Dr. Ahmed [email protected]
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

Metrics & Citations

Metrics

Citation information is sourced from Crossref Cited-by service.

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Unraveling the Genetic Landscape of Neurological Disorders: Insights into Pathogenesis, Techniques for Variant Identification, and Therapeutic Approaches, International Journal of Molecular Sciences, 25, 4, (2320), (2024).https://doi.org/10.3390/ijms25042320
    Crossref
  2. Unraveling the Heterogeneity of ALS—A Call to Redefine Patient Stratification for Better Outcomes in Clinical Trials, Cells, 13, 5, (452), (2024).https://doi.org/10.3390/cells13050452
    Crossref
  3. Risk factors for the neurodegenerative dementias in the Western Pacific region, The Lancet Regional Health - Western Pacific, 50, (101051), (2024).https://doi.org/10.1016/j.lanwpc.2024.101051
    Crossref
  4. Metabolite alterations in the left dorsolateral prefrontal cortex and its association with cognitive assessments in amyotrophic lateral sclerosis: A longitudinal magnetic resonance spectroscopy study, Brain Research Bulletin, 219, (111125), (2024).https://doi.org/10.1016/j.brainresbull.2024.111125
    Crossref
  5. Corticobasal Syndrome (CBS), Movement Disorders Phenomenology, (199-236), (2024).https://doi.org/10.1007/978-3-031-52573-5_6
    Crossref
  6. Cognitive disorders in amyotrophic lateral sclerosis, Neurology, Neuropsychiatry, Psychosomatics, 15, 2, (68-74), (2023).https://doi.org/10.14412/2074-2711-2023-2-68-74
    Crossref
  7. Short tandem repeat expansions in sporadic amyotrophic lateral sclerosis and frontotemporal dementia, Science Advances, 9, 18, (2023).https://doi.org/10.1126/sciadv.ade2044
    Crossref
  8. Severity of in vivo corticospinal tract degeneration is associated with survival in amyotrophic lateral sclerosis: a longitudinal, multicohort study, European Journal of Neurology, 30, 5, (1220-1231), (2023).https://doi.org/10.1111/ene.15686
    Crossref
  9. Prognostic value of motor and extramotor involvement in ALS, Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 25, 1-2, (67-74), (2023).https://doi.org/10.1080/21678421.2023.2284899
    Crossref
  10. MRI biomarkers for memory-related impairment in amyotrophic lateral sclerosis: a systematic review, Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 24, 7-8, (572-588), (2023).https://doi.org/10.1080/21678421.2023.2236651
    Crossref
  11. See more
Loading...

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Short Form

View Short Form

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share